Financial Results for the quarter and half year ended September 30,2025
ALPA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alpa Laboratories reported standalone revenue from operations of ₹2,563 lacs for Q2 FY26, up modestly from ₹2,494 lacs in Q2 FY25 (~2.8% YoY). H1 FY26 revenue came in at ₹4,474 lacs, down about 3.5% from ₹4,638 lacs in H1 FY25. Profit after tax collapsed sharply to just ₹5.76 lacs in Q2 FY26 versus ₹762.81 lacs in Q2 FY25, with H1 FY26 PAT at ₹187.93 lacs versus ₹277.03 lacs in H1 FY25 (~32% decline). The Q2 weakness was largely driven by the absence of a deferred tax credit that boosted the year-ago quarter; no exceptional items were recorded this quarter. The statutory auditor (C.H. Padliya & Co.) issued an unqualified limited review report on both standalone and consolidated results. Operating cash flow remained healthy at ₹1,215 lacs for H1 standalone, and the balance sheet shows minimal leverage with only ₹234 lacs of short-term borrowings against other equity of over ₹17,263 lacs.
Despite stable top-line numbers, the sharp Q2 PAT slump is likely to weigh on investor sentiment and could put short-term pressure on the stock. The company's overall financials, cash generation, and balance sheet remain sound, so the weakness looks more like a one-quarter tax-driven distortion than a structural problem.